Disclosed is the use of an antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12 and or IL-23, in the preparation of a medicament for treating psoriasis in a subject, wherein the subject exhibits at least a PASI 75 response by week 12 of a first extended period following initial administration of the medicament, wherein the subject exhibits a loss of response following discontinuation of administration of the medicament, and wherein the subject exhibits at least a PASI 50 response by week 12 of a second extended period following re-administration of the medicament.
